We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

AstraZeneca, Peregrine Pharmaceuticals Collaborate

News   Aug 25, 2015

 
AstraZeneca, Peregrine Pharmaceuticals Collaborate
 
 
Advertisement
 

RELATED ARTICLES

Asthma Drug Reduces Recovery Time in Non-Hospitalized Patients With COVID-19

News

Inhaled budesonide, has been found to shorten recovery times in COVID-19 patients aged over 50 years who are treated at home and in other community settings, according to the UK’s PRINCIPLE trial of 1,779 participants.

READ MORE

Prioritizing Drugs Targeting IFNAR2 and ACE2 To Treat COVID-19

News

Researchers have used human genetics in a new study and the findings suggest researchers should prioritize clinical trials of drugs that target the proteins IFNAR2 and ACE2 to manage COVID-19 in its early stages.

READ MORE

Personalized Cancer Vaccine Shows Early Efficacy in Patients With Diverse Tumor Types

News

Treatment with the neoantigen cancer vaccine PGV-001 following standard-of-care adjuvant therapy was well tolerated and demonstrated potential clinical benefit in patients with diverse tumor types according to a Phase 1 study. The findings were reported during the virtual AACR Annual Meeting 2021.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE